-+ 0.00%
-+ 0.00%
-+ 0.00%

Moleculin reports pooled analysis shows no cardiotoxicity signal for Annamycin in five trials

PUBT·09/28/2026 11:03:15
Moleculin reports pooled analysis shows no cardiotoxicity signal for Annamycin in five trials
  • Moleculin Biotech reported peer-reviewed results from a pooled analysis of five Annamycin trials published in Frontiers in Cardiovascular Medicine.
  • Findings were previously presented in clinical updates, now reinforced by journal publication and an independent Cleveland Clinic cardio-oncology review.
  • The analysis found no signs of treatment-related heart damage, supporting Annamycin’s positioning as a potentially safer anthracycline.
  • Data came from 90 patients in AML or metastatic soft tissue sarcoma, supporting continued development in the MIRACLE program for relapsed or refractory AML.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280700PRIMZONEFULLFEED9834355) on September 28, 2026, and is solely responsible for the information contained therein.